Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide.

Official Title
-----------------
A Multicenter, Retrospective, Medical Record Review Of The Effectiveness Of Lanreotide Following Treatment With Octreotide In Patients With Neuroendocrine Tumors

Conditions
-----------------
Neuroendocrine Tumors

Intervention / Treatment
-----------------
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females age 18 years or older at time of locally advanced or metastatic diagnosis Patients with a confirmed diagnosis of locally advanced or metastatic Gastroenteropancreatic neuroendocrine tumour (GEP-NET) Patients who switched treatment from long acting octreotide LAR to lanreotide, where both treatments were received for the treatment of locally advanced or metastatic GEP-NET. i. Treatment with long acting octreotide LAR monotherapy for at least 90-days before treatment with lanreotide monotherapy (rescue SSA# use permitted). ii. Treatment with lanreotide monotherapy for at least 90-days after treatment with long acting octreotide monotherapy (rescue SSA# use permitted) Exclusion Criteria: Patients with other malignant disease Patients who participated in a concomitant clinical trial related to treatment of GEP-NET Patients being treated with a Somatostatin analogue (SSA) in combination with other NET treatments excluding rescue SSA# Patients who received other primary treatment (e.g., targeted therapy, chemotherapy) for GEP-NET during the interval between octreotide and lanreotide Patients with NET familial genetic syndrome (i.e., MEN1)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Data collection|This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response to treatment | Evaluated as responsive disease (i.e., complete response, partial response), stable disease or progressive disease at the last tumor assessment while on treatment with lanreotide (based on tumor imaging, symptoms, biomarker(s) and/or clinical judgement) | 4 months (data collection duration) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival, after treatment with octreotide | For evaluating progression-free survival events will include radiographic progression per investigator, biomarker progression per investigator, symptom progression per investigator, and death. Adverse events (AEs) will not be considered as an event. | 4 months (data collection duration) | 
| Duration of response to lanreotide, after treatment with octreotide | For evaluating duration of response events will include radiographic progression per investigator, biomarker progression per investigator, symptom progression per investigator, AEs, and death. Open ended responses will be reviewed during the analysis and determined to be an eligible event or not at that time. | 4 months (data collection duration) | 
| Duration of treatment with octreotide and duration of treatment with lanreotide | Duration of octreotide treatment assessed as time from start of octreotide treatment to stop of octreotide treatment. Duration of lanreotide treatment assessed as time from lanreotide initiation to end of lanreotide treatment (censored at the date of last administration (+lanreotide frequency) for patients who had ongoing lanreotide treatment). | 4 months (data collection duration) | 
| Severity of Adverse Events | Summarized separately during treatment with octreotide and during treatment with lanreotide, as available | 4 months (data collection duration) | 
| Reasons for switching from octreotide to lanreotide | Summarized descriptively | 4 months (data collection duration) | 
| Levels of 5-hydroxyindoleacetic acid (5-HIAA) (urine test or blood test) before treatment with octreotide, during treatment with octreotide and during treatment with lanreotide, as available | Summarized descriptively | 4 months (data collection duration) | 
| Levels of Chromogranin A (CgA) before treatment with octreotide, during treatment with octreotide and during treatment with lanreotide, as available | Summarized descriptively | 4 months (data collection duration) | 
| Severity of symptoms (i.e., flushing, diarrhea, dyspnea, abdominal pain, edema, nausea) before treatment with octreotide, during treatment with octreotide, and during treatment with lanreotide, as available | Proportion of patients reporting each symptom | 4 months (data collection duration) |